ARTICLE | Clinical News
XR5000: Began Phase II testing
November 22, 1999 8:00 AM UTC
Xenova Group plc (LSE:XEN; XNVA), Slough, U.K. Product: XR5000 Business: Cancer Therapeutic category: Cytotoxic Target: Topoisomerase I and II Description: Inhibitor of both topoisomerase I and II In...